Hidden Hieroglyphs Discovered on Ancient Egyptian Obelisk in Paris
The findings were made during the first full expert examination of the Luxor Obelisk's upper sections since 1836.
Apr 24, 2025
Seven previously unknown messages have been identified on the 3,000-year-old Luxor Obelisk in Paris, long believed to be fully deciphered.
The 75-foot granite monument, carved during the reign of Ramses II and gifted to France in the 19th century, stands at Place de la Concorde. During recent access enabled by Olympic renovation scaffolding, Egyptologist Dr Jean-Guillaume Olette-Pelletier of Paris-Sorbonne University found the encrypted texts using his expertise in crypto-hieroglyphs. Among the inscriptions is a phrase invoking the 'ka-force of Amun,' suggesting symbolic appeals to divine power.
The findings, made during the first full expert examination of the obelisk's upper sections since its 1836 installation, will be published in the Montpellier-based Egyptology journal ENIM . Only one of two Luxor Obelisks, its twin remains in Luxor, Egypt and may hold additional undiscovered texts.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Middle East
22-05-2025
- Middle East
OPEN// PM meets Oxford university delegation for talks on coop. in advanced cancer treatment
CAIRO, May 22 (MENA) - Prime Minister Moustafa Madbouli met with a delegation from the University of Oxford at the government headquarters in the New Administrative Capital to discuss collaboration on advanced cancer treatment and medical research. Attendees included Egypt's Minister of Higher Education and Scientific Research Ayman Ashour, Cairo University President Mohamed Sami Abdel Sadek and Oxford's Pro-Vice Chancellor for Innovation Chas Bountra. The discussions centered on a new and advanced cancer treatment method developed by Oxford along with ways to transfer this technology to Egypt, particularly through partnerships with Cairo University and Hospital 500/500. Representatives from Caring Cross and GermFree, US-based organizations specializing in gene and cell therapies and cleanroom infrastructure, outlined plans for cooperation with Egypt to make cutting-edge cancer treatments more affordable and accessible. Brazil and India are already engaged in similar collaborations, they pointed out. The proposed project includes establishing Egypt's first applied research center for advanced medical products, training medical staff, and creating a national platform for gene and cell therapy development—positioning Egypt as a regional leader in this field. Madbouli expressed full support for the project and directed the preparation of an implementation plan. He also proposed adopting it as a national initiative, similar to Egypt's successful Hepatitis C treatment campaign, to expand access and reduce costs for cancer patients nationwide. (MENA) M H K/R E E
Mid East Info
22-05-2025
- Mid East Info
The Environment Agency – Abu Dhabi Successfully Disperses 6.5 Million Native Seeds Across its Nature Reserves Using Drones
To enhance vegetation cover and rangelands across the emirate of Abu Dhabi As part of its continued drive to adopt cutting-edge technologies that support biodiversity in the emirate of Abu Dhabi, the Environment Agency – Abu Dhabi (EAD) has completed its 2025 native seed dispersal programme in nature reserves. The initiative, conducted in partnership with UK-based environmental restoration company Dendra, used custom-designed drones to carry out aerial seeding. The Agency continues to advance its drone-based seeding programme through the expertise of a dedicated team comprising seasoned professionals and promising young Emirati talent. The team carries out comprehensive studies and precise assessments of vegetation cover within the targeted reserves, taking into account soil characteristics and their suitability for the native plant species selected under the programme. Commenting on the initiative, Ahmed Al Hashmi, Executive Director of the Terrestrial and Marine Biodiversity Sector at EAD, stated: 'We successfully implemented one of the largest drone-based seeding operations ever undertaken in the emirate of Abu Dhabi, within a notably short timeframe. This achievement is in line with Abu Dhabi's Climate Change Strategy and covered a total of 320 hectares of habitat, many of which were seeded for the first time.' He added: 'This initiative underscores the Agency's commitment to harnessing advanced artificial intelligence tools in support of environmental sustainability and reflects our leadership's ongoing vision to safeguard natural ecosystems through the integration of innovation and technology in pursuit of the UN's Sustainable Development Goals.' A total of 6.5 million seeds from native species were dispersed, including Samar ( Vachellia tortilis ), Moringa ( Moringa peregrina ), Rumex ( Rumex limoniastrum ), Cleome ) Cleome pallida (, Desert cotton ( Aerva javanica ) and Panicum ( Panicum turgidum ) in the mountainous slopes and wadi habitats of Jebel Hafit National Park. As for the Sand dunes ecosystems of Qasr Al Sarab Nature Reserve, seeds of Fire Bush ( Calligonum polygonoides ), Rimth ( Haloxylon salicornicum ), Tricholaena ( Tricholaena teneriffae ), Panicum ( Panicum turgidum ), and Agriophyllum ( Agriophyllum minus) were distributed. The use of drones enables the Agency to cover extensive areas in significantly less time compared to traditional manual seeding methods. This technology also facilitates operations in remote and difficult-to-access terrain without the need for vehicles, thereby reducing environmental disturbance to fragile ecosystems. Seeding marks only the beginning of the process. EAD will continue to monitor the designated areas to assess vegetation response over time, employing AI-powered sensors and advanced monitoring technologies to track the growth of shrubs and native plants. This initiative builds upon the natural rangeland study programmes launched by the Agency in 2024 and are continuing into 2025. These efforts aim to establish a comprehensive, field-based assessment of current vegetation conditions, serving as a benchmark for evaluating the effectiveness of grazing regulations and other environmental management measures across the emirate of Abu Dhabi. About Environment Agency – Abu Dhabi (EAD) Established in 1996, the Environment Agency – Abu Dhabi (EAD) is committed to protecting and enhancing air quality, groundwater as well as the biodiversity of our desert and marine ecosystem. By partnering with other government entities, the private sector, NGOs and global environmental agencies, we embrace international best practice, innovation and hard work to institute effective policy measures. We seek to raise environmental awareness, facilitate sustainable development and ensure environmental issues remain one of the top priorities of our national agenda.
Egypt Independent
18-05-2025
- Egypt Independent
FDA greenlights first blood test to help diagnose Alzheimer's disease in the US
The US Food and Drug Administration has given marketing clearance to a blood test to help diagnose Alzheimer's disease, making the test the first to get signoff to aid in the early detection of the disease in the United States. The test, called the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, is for adults 55 and older who are showing signs and symptoms of Alzheimer's disease, the FDA announced Friday. It works by measuring two proteins in blood plasma: pTau217 and beta-amyloid 1-42. A ratio of those proteins tends to correlate with the occurrence or absence of amyloid plaques in the brain, which are among the hallmarks of Alzheimer's disease. The test does not measure amyloid directly but can signal its presence. However, there remains no current single test to diagnose Alzheimer's disease. Doctors primarily rely on a variety of tools to diagnose the condition, which may include medical history, neurological exams, cognitive and functional evaluations, brain imaging, spinal fluid analysis and, more recently, blood tests. The FDA said the results of the newly cleared blood test must be assessed in conjunction with other clinical information from a patient. 'Alzheimer's disease impacts too many people, more than breast cancer and prostate cancer combined,' FDA Commissioner Dr. Martin Makary said in Friday's announcement. 'Knowing that 10% of people aged 65 and older have Alzheimer's, and that by 2050 that number is expected to double, I am hopeful that new medical products such as this one will help patients.' According to the FDA, the new blood test – developed by the Pennsylvania-based biotechnology company Fujirebio Diagnostics Inc. – can help increase access to Alzheimer's disease detection and reduce reliance on positron emission tomography or PET scans, a type of imaging that can reveal amyloid plaques in the brain but can be expensive, costing thousands of dollars without insurance. The FDA said it reviewed clinical trial data on the new blood test, involving plasma samples collected from 499 adults who were cognitively impaired. The samples were evaluated using the blood test, and the results were compared with the results from patients' PET scans or separate testing using cerebrospinal fluid samples, such as from spinal taps. The data showed that 91.7% of adults with positive results using the blood test had the presence of amyloid plaques confirmed by their PET scan or cerebrospinal fluid test, and 97.3% of people with negative results had a negative amyloid PET scan or cerebrospinal fluid test result, according to the FDA. The agency added that the risks associated with the blood test are mainly the risk of a false positive or false negative test result. A 'new era' of Alzheimer's research Preventive neurologist Dr. Richard Isaacson, who established one of the first Alzheimer's prevention clinics in the United States, said he has been using this blood test for years for research and applauded the FDA clearance. 'It can provide better clarity into whether a person experiencing memory loss may have Alzheimer's disease. They can take this test as a screening test,' said Isaacson, director of research at the Institute for Neurodegenerative Diseases in Florida. Compared with costly PET scans or spinal taps, 'this is a much more simple screening test, with reasonable accuracy, to tell the physician that a person with cognitive decline has symptoms that are actually due to Alzheimer's disease.' But Isaacson warned that while the FDA clearance is 'an important step forward' for the field, more research is needed to help inform how blood test results should be interpreted and used to make clinical decisions. 'I think the next step as a field is, we need to advance education about what these tests mean and what they don't and who they should be used for,' he said. 'Because they mean different things in different people depending on their risk factors and whether or not they have symptoms. So we're still early.' Fujirebio Diagnostics designed the blood test to help detect Alzheimer's disease early, when interventions are more effective, president and CEO Monte Wiltse said in a news release last year , when the company filed its test with the FDA. 'An early and accurate diagnosis will also facilitate the development of new drug therapies, which are urgently needed as the prevalence of AD increases with a rapidly aging population globally,' Wiltse said. It's estimated that more than 2 in 5 people over the age of 55 in the United States – about 42% – will develop dementia in their later years. But in some cases, deposits of amyloid can start to accumulate in the brain decades before Alzheimer's symptoms begin. Early detection of these amyloid plaques could open the door for a person to take steps to slow the progression of disease, such as starting preventive treatment with medications. 'For too long Americans have struggled to get a simple and accurate diagnosis, with today's action by the FDA we are hopeful it will be easier for more individuals to receive an accurate diagnosis earlier,' Dr. Maria Carrillo, chief science officer and medical affairs lead at the Alzheimer's Association, said in a statement Friday. There are a variety of laboratory-developed tests on the market that can be used to detect blood-based biomarkers associated with Alzheimer's, according to the Alzheimer's Association, as well as experimental tests. But the Fujirebio Diagnostics test is the first one cleared by the FDA. 'Blood-based biomarkers are reshaping how we identify and understand Alzheimer's disease,' Carrillo said. 'At the same time, there are important questions for health care professionals to consider; in particular, who should be tested and when.' For now, the FDA's clearance 'marks a major milestone,' said Dr. Howard Fillit, co-founder and chief science officer at the Alzheimer's Drug Discovery Foundation. 'The ability to diagnose Alzheimer's earlier with a simple blood test, like we do for cholesterol, is a game changer, allowing more patients to receive treatment options that have the potential to significantly slow or even prevent the disease,' Fillit said in an email Friday. 'This is a clear example of the new era of Alzheimer's research where innovation, science and technology come together to develop more accessible, affordable and scalable tools that will pave the way for additional regulatory approvals of diagnostic tools.'
